The Chicago Entrepreneur

: What investors need to know about Pfizer’s latest downgrade

The company’s pipeline, though promising, is still too premature to make up for the looming drop in COVID-19 franchise revenue.

Previous post Earnings Results: Visa rides a wave of spending to an earnings beat
Next post Tesla in 2023: A Return to Reality, The Start of the End or Time to Buy?